logo
CanyamAI summaries for academic research
language
MobileMobile
  • Phone FeatureWeChat Mini Program
EnglishEnglish
noticeNotice
BlogBlog
delete
arrow
Back
H

Hospital De Base De SãO José Do Rio Preto

Scholars2
Papers2
Citations0
Related Papers (2)
Publication Date
delete
Prostate-specific Antigen and Objective Response Analyses in PROpel: Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone as First-line Therapy for Metastatic Castration-resistant Prostate Cancer
errEuropean Urology Oncology
IF9.3
err2025-11-04
err0
errOAAI
errFred Saad; Andrew J. Armstrong; Mototsugu Oya; Neal Shore; Giuseppe Procopio; João Daniel Guedes; Cagatay Arslan; Niven Mehra; Emma Brown; Jae Young Joung; Mikio Sugimoto; Oliver Sartor; Christian Poehlein; Elizabeth A. Harrington; Jinyu Kang; Noel Clarke
errShare
errSave
Efficacy and Safety of Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone in the First-line Treatment of Patients with Asymptomatic/Mildly Symptomatic and Symptomatic Metastatic Castration-resistant Prostate Cancer: Analyses from the Phase 3 PROpel Trial
errEuropean Urology Oncology
IF9.3
err2024-10-01
err0
errOAAI
errNoel W. Clarke; Andrew J. Armstrong; Mototsugu Oya; Neal Shore; Giuseppe Procopio; João Daniel Guedes; Cagatay Arslan; Niven Mehra; Francis Parnis; Emma Brown; Friederike Schlürmann; Jae Young Joung; Mikio Sugimoto; Oliver Sartor; Christian Poehlein; David McGuinness; Arnold Degboe; Fred Saad
errShare
errSave